PLAU and neoplasm: In the presence of pro-uPA and plasminogen, the recombinant complex (PrAg-U2 + FP59) was demonstrated to be activated selectively on the surface of uPAR-expressing tumor cells from a broad range of human cancers of different origins, and ultimately resulted in specific tumor cell eradication [425,427].